Next 10 |
2024-10-10 11:59:56 ET More on Seres Therapeutics Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript Seres Therapeutics jumps on report of Nestle acquisition offer Seres Thera...
2024-10-01 17:01:35 ET More on Seres Therapeutics Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript Seres Therapeutics jumps on report of Nestle acquisition offer Seres Thera...
Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable patient populations at high risk of life-threatening bacterial infections Cash received at completion, along with a...
CAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that its stockholders voted to approve the previously announced proposed sale of the C...
2024-09-23 00:14:32 ET Summary Seres Therapeutics' sale of VOWST to Nestlé extends its cash runway to Q4 2025, addressing near-term financial concerns. MCRB will receive a $100 million upfront payment, with approximately $20 million used to settle net obligations. It also get...
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that the Company, will participate in the Cantor Global Healthcare Conference and Eric Shaff, President and Chief Executive Officer, will represent...
SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as compared to placebo through day 100 post HSCT Demonstrated generally well tolerated ...
2024-09-06 10:49:33 ET More on Seres Therapeutics Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript Seres Therapeutics GAAP EPS of -$0.22 beats by $0.06 Nestlé agrees to buy microbiome therapy Vowst from Seres Seeking Alpha’s Quant ...
2024-08-13 15:35:28 ET Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Conference Call August 13, 2024, 08:30 AM ET Company Participants Carlo Tanzi - IR Eric Shaff - CEO Lisa von Moltke - Chief Medical Officer Marella Thorell - CFO Matthew Henn - EVP, C...
2024-08-13 07:02:21 ET More on Seres Therapeutics Nestlé agrees to buy microbiome therapy Vowst from Seres Nestlé to buy microbiome therapy Vowst from Seres Seeking Alpha’s Quant Rating on Seres Therapeutics Historical earnings data for Seres...
News, Short Squeeze, Breakout and More Instantly...
Seres Therapeutics Inc. Company Name:
MCRB Stock Symbol:
NASDAQ Market:
Seres Therapeutics Inc. Website:
Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable patient populations at high risk of life-threatening bacterial infections Cash received at completion, along with a...
CAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that its stockholders voted to approve the previously announced proposed sale of the C...
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that the Company, will participate in the Cantor Global Healthcare Conference and Eric Shaff, President and Chief Executive Officer, will represent...